MedPath

Multi-sensory Intervention Room Application (MIRA) Device in the NSICU

Not Applicable
Recruiting
Conditions
Post Intensive Care Syndrome
Interventions
Device: MIRA
Registration Number
NCT06509815
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Brief Summary

The purpose of this research study is to determine the safety, feasibility, and efficacy of a device, MIRA, on the physical, mental, and cognitive health of Neurosciences Intensive Care Unit (NSICU) patients.

The study device is a Multi-Sensory Stimulation Device named MIRA, which uses commercially available hardware and builds off the SOLUNA software created by Studio Elsewhere, which produces audio and visual immersive experiences. The current device, Model M1, is a prototype developed for sole investigational purposes of this study and is not commercially available.

Participants, who will be patients and staff of the NSICU, will complete questionnaires regarding safety, feasibility, and efficacy. The research team will enroll 20 patient and 15 staff participants. The trial is expected to last 12 months.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria

To be eligible to participate in this study, an individual must meet all of the following criteria:

For NSICU Staff:

  • Current employee at NSICU
  • Aged >/= 18

For NSICU Patients:

  • Currently admitted to the Mount Sinai Hospital NSICU for any diagnosis OR a Legally Authorized Representative (LAR) for the patient, and expected to stay for at least 48 hours
  • Provision of signed and dated informed consent form (ICF)
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Aged >/= 18
  • Any sex or gender identity
  • Currently admitted to the Mount Sinai Hospital NSICU for any diagnosis OR a Legally Authorized Representative (LAR) for the patient, and expected to stay for at least 48 hours

Exclusion Criteria

  • Not a Mount Sinai NSICU patient
  • No LAR present and unable to consent
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
MIRA in the NSICUMIRAThe Intervention arm will experience the device, MIRA, during their stay in the NSICU.
Primary Outcome Measures
NameTimeMethod
Acceptability of Intervention Measure (AIM)Within 2 days of the device used in the patient room during stay in ICU

Implementation success will be assessed using the Acceptability of Intervention Measure (AIM). AIM is a 4-item measure used to determine the extent to which stakeholders (e.g., parents, providers, administrators) believe an intervention or implementation strategy is acceptable. Total score ranges from a minimum score 4 (unacceptable) to a maximum score 20 (very acceptable), with higher scores indicating greater acceptability of the intervention.

Feasibility of Intervention Measure (FIM)Within 2 days of the device used in the patient room during stay in ICU

Implementation success will be assessed using the Feasibility of Intervention Measure (FIM). FIM is a 4-item measure used to determine the extent to which an intervention or implementation strategy is feasible to implement. Total score ranges from a minimum of 4 (not feasible) to a maximum of 20 (very feasible), with higher scores indicating greater perceived feasibility of the intervention strategy being evaluated.

Intervention Appropriateness Measure (IAM)Within 2 days of the device used in the patient room during stay in ICU

Implementation success will be assessed using the Intervention Appropriateness Measure (IAM). IAM is a 4-item measure used to determine the extent to which stakeholders (e.g. parents, providers, administrators) believe an intervention or implementation strategy is appropriate or suitable for the situation. Total score ranges minimum 4 (unacceptable) to maximum 20 (very acceptable), with higher scores indicating greater appropriateness of the intervention strategy being evaluated.

Secondary Outcome Measures
NameTimeMethod
Type of pain medication administrationdaily, average 4 days in ICU

Categorical information on the type of medication administered (sedatives, analgesics, anti-seizure medications, anti-hypertensives, pressors, antibiotics, antipsychotics, other)

Patient Health Questionnaire 9 (PHQ9) Scale ScoreUp to 6 months

The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report tool used to assess depression severity. PHQ-9 scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

Response to noxious stimuli and/or touchUp to 6 months

Neurological assessment used to assess sensory status. Sensory status notes if the patient responds to noxious stimuli or not.

Generalized Anxiety Disorder 7 Scale ScoreUp to 6 months

The Generalized Anxiety Disorder 7-item (GAD-7) scale is used to assess self-reported anxiety symptoms. Total GAD-7 score ranges from a minimum of 0 (no anxiety) to a maximum of 21 (severe anxiety), with higher scores indicating greater anxiety severity.

Intubated pain measured using Critical Care Pain Observation Tooldaily, average 4 days in ICU

The Critical Care Pain Observation Tool (CCPOT) is an 8-item measure used to assess self-reported pain levels in intubated, critically ill patients who cannot self-report. Total CCPOT score ranges from a minimum of 0 (no pain behaviors observed) to a maximum of 8 (significant behaviors indicating severe pain), with higher scores indicating higher pain levels in intubated patients.

Patient Health Questionnaire 2 (PHQ2) Scale ScoreUp to 6 months

The Patient Health Questionnaire-2 (PHQ-2) is a 2-item screening tool used to assess depressed mood and anhedonia to screen for depression. PHQ-2 scores range from 0 to 6, with higher scores suggesting a higher likelihood of depression requiring further evaluation with the longer PHQ-9.

Motor StatusUp to 6 months

Neurological assessment used to asses motor status. Motor strength is ranked 0-5 (5 meaning full function) for both upper and lower extremities.

Insomnia Severity Index to measure sleep qualityUp to 6 months

The Insomnia Severity Index (ISI) is a 7-item questionnaire used to assess perceived insomnia severity. ISI scores range from 0 to 28, with higher scores indicating more severe levels of insomnia.

Non-intubated pain measured using Pain Scaledaily, average 4 days in ICU

The Pain Scale is used to assess self-reported pain levels in critically ill patients who are not intubated and can self-report pain. Total score on the Pain Scale ranges from a minimum of 0 (no pain) to a maximum of 10 (worst/most severe pain), with higher scores indicating more intense pain levels in non-intubated patients.

Awareness of person, place, and timeUp to 6 months

Neurological assessment used to assess mental status. Mental status checks if a person has awareness of person, place, and time.

Trial Locations

Locations (1)

Mount Sinai Hospital

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath